Humacyte Inc (HUMA)vsNovartis AG ADR (NVS)
HUMA
Humacyte Inc
$1.39
-4.14%
HEALTHCARE · Cap: $299.73M
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2806348% more annual revenue ($56.58B vs $2.02M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
HUMA
Avoid14
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+55.3%
Fair Value
$2.26
Current Price
$1.39
$0.87 discount
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 27.8x book value
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : HUMA
HUMA has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : HUMA
The primary concerns for HUMA are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 5.67 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
HUMA profiles as a value stock while NVS is a declining play — different risk/reward profiles.
HUMA carries more volatility with a beta of 2.46 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 14/100), backed by strong 23.9% margins. HUMA offers better value entry with a 55.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Humacyte Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Humacyte Inc (HUMA) is an innovative biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs) aimed at addressing critical clinical demands in vascular reconstruction and chronic disease management. By offering off-the-shelf solutions, Humacyte enhances patient outcomes while aiming to reduce overall healthcare expenditures. Leveraging its cutting-edge technology platform, the company is well-positioned to lead advancements in transplantation and tissue engineering, establishing itself as a key player in the rapidly evolving medical therapies sector.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?